Company overview
Basic information
Company name
ARLE, UAB
Company code
302833905
VAT code
LT100009056310
Registered address
Vilnius, Sirpučių g. 34, LT-02239
Registration date
2012-08-03
Company age: 14 y. 2 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
https://www.arle.lt
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
New construction
Ownership form
Private without foreign capital
UAB "ARLE"
Company code: 302833905
Address: Vilnius, Sirpučių g. 34, LT-02239
VAT code: LT100009056310
Description
This description was generated by artificial intelligence.
ARLE, UAB (company code 302833905) is an operational private limited liability company registered in 2012 and based in Vilnius, Sirpuciu g. 34, Vilniaus m. sav., Vilniaus apskr. It operates as a private company in the national private non-financial sector, with a governance model described as CEO only and ownership structure classified as private property with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. The company’s activity is recorded under EVRK code F.41.00.10, New construction. ARLE is classified as a micro company and its share capital is €2.9K. Financially, 2025 was a very small-revenue year at €10.5K, but the company remained profitable with net profit of €1.9K and a margin of 18.3%. This followed much higher revenue in 2024 and 2023, indicating a pronounced decline in turnover over the latest year. The balance sheet remained very small, with positive equity of €146 and liabilities of €83 at the end of 2025. The company employed 4 people on average in 2025 and also so far in 2026. The average monthly wage was €153.26 so far in 2026, down from €165.90 in 2025 and €288.11 in 2024.
Download a detailed company report
Make confident decisions with all the information about ARLE, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.